Jane Street
NTLA icon

Jane Street’s Intellia Therapeutics NTLA Stock Holding History

Jane Street’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.32M Buy
414,700
+194,000
+88% +$2.47M ﹤0.01% 3419
2025
Q4 		$1.98M Buy
220,700
+123,500
+127% +$1.7M ﹤0.01% 4824
2025
Q3 		$1.68M Buy
97,200
+34,200
+54% +$421K ﹤0.01% 5261
2025
Q2 		$591K Sell
63,000
-8,400
-12% -$69K ﹤0.01% 6604
2025
Q1 		$508K Buy
+71,400
New +$721K ﹤0.01% 6834
2024
Q4 		– Sell
-56,100
Closed -$1.15M – 10190
2024
Q3 		$1.15M Sell
56,100
-231,500
-80% -$5.34M ﹤0.01% 5610
2024
Q2 		$6.44M Buy
287,600
+195,600
+213% +$4.66M ﹤0.01% 2613
2024
Q1 		$2.53M Buy
92,000
+36,900
+67% +$1.02M ﹤0.01% 3713
2023
Q4 		$1.68M Buy
55,100
+11,700
+27% +$336K ﹤0.01% 4638
2023
Q3 		$1.37M Sell
43,400
-32,500
-43% -$1.26M ﹤0.01% 4680
2023
Q2 		$3.1M Buy
75,900
+54,500
+255% +$2.21M ﹤0.01% 3438
2023
Q1 		$798K Sell
21,400
-16,900
-44% -$663K ﹤0.01% 5444
2022
Q4 		$1.34M Sell
38,300
-72,700
-65% -$3.46M ﹤0.01% 4506
2022
Q3 		$6.21M Buy
111,000
+11,300
+11% +$701K ﹤0.01% 2289
2022
Q2 		$5.16M Buy
99,700
+19,400
+24% +$985K ﹤0.01% 2615
2022
Q1 		$5.83M Buy
80,300
+45,900
+133% +$3.89M ﹤0.01% 2781
2021
Q4 		$4.07M Sell
34,400
-21,800
-39% -$2.73M ﹤0.01% 3175
2021
Q3 		$7.54M Sell
56,200
-120,600
-68% -$18.3M ﹤0.01% 2180
2021
Q2 		$28.6M Buy
176,800
+121,700
+221% +$9.48M 0.01% 838
2021
Q1 		$4.42M Sell
55,100
-27,900
-34% -$1.87M ﹤0.01% 2578
2020
Q4 		$4.51M Buy
+83,000
New +$3.01M ﹤0.01% 2263

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street's NTLA Position: Q1 2026 in Review

Jane Street increased its Intellia Therapeutics (NTLA) stake by 16% in Q1 2026, buying an estimated $669K and bringing the position to 384,957 shares worth $4.94M. The position accounts for ﹤0.01% of the portfolio, ranked #3540.

Jane Street first reported a position in NTLA in Q2 2020 and has held it in 24 quarters since. The position peaked at $8.37M in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Jane Street held 384,957 shares of Intellia Therapeutics worth $4.94M as of Q1 2026.
  • Jane Street bought 52,486 Intellia Therapeutics shares in Q1 2026, an estimated $669K.
  • Intellia Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3540 holding.
  • Jane Street first reported a position in Intellia Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Jane Street's Intellia Therapeutics position peaked at $8.37M in Q2 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.